Carmustine vindesine and tamoxifen in patients with metastatic mammary carcinoma no longer responsive to cyclo phosphamide vincristine adriamycin and 5 fluoro uracil methotrexate cyclo phosphamide

Massner, B.; Voss, I.; Quisser, W.; Drings, P.; Fritze, D.; Westerhausen, M.

Onkologie 5(SPEC ISSUE): 46, 49-51


ISSN/ISBN: 0378-584X
Accession: 004884171

Download citation:  

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Looking for an alternative treatment for patients with advanced breast carcinoma resistant to the common treatment regimens, vindesine, carmustine (BCNU [1,3-bis-(2-chloroethyl)-1-nitrosourea]) and tamoxifen were used for further treatment. Twenty-seven patients were admitted to a 2-step treatment schedule including a step I with tamoxifen alone and a step II with vindesine, carmustine and tamoxifen. Within the step I with tamoxifen, 7 of 14 patients (50%), and within the consecutive step II with vindesine, carmustine and tamoxifen, 4 of 20 patients (20%) responded to this regimen. The mean duration of the response was +7.4 and +9.0 mo., respectively. Effective palliation probably is still possible in some patients suffering from progressive disease after therapy with vincristine + adriamycin + cyclophosphamide and 5-fluorouracil + methotrexate + cyclophosphamide.